— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.
— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.
— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.
— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.
— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.
— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.
— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.
Most Popular
Spotify (SPOT) Earnings: 3Q24 Key Numbers
Spotify Technology S.A. (NYSE: SPOT) reported total revenue of EUR3.98 billion for the third quarter of 2024, up 19% year-over-year. Net income attributable to owners of the parent was EUR300
Nvidia (NVDA) looks poised to deliver blowout results once again
After a blockbuster first half, Nvidia Corporation (NASDAQ: NVDA) is preparing to publish data on its third-quarter financial performance next week. Since the company is expected to provide updates on
Key takeaways from Tyson Foods’ (TSN) Q4 2024 earnings report
Shares of Tyson Foods, Inc. (NYSE: TSN) jumped over 8% on Tuesday after the company delivered better-than-expected earnings results for the fourth quarter of 2024. Revenue and earnings beat estimates,